Infliximab for Psoriasis

Title: Infliximab Role in the Treatment of Psoriasis
: Mossner R and Reich K
Publication: Hautarzt. 2005 Sep;56(9):831-8.

In psoriasis, Th1 cells-mediated immune responses are considered crucial. Th1 cell is a subset of T-helper lymphocyte (white blood cell) that is involved in cell-mediated immune response. The Th1 cells secretes cytokines, or proteins that mediate immune system response, including one called TNF-alpha or tumor necrosis factor alpha.

The authors reviewed clinical studies on infliximab, an antibody that bound and disabled Th1-cytokine TNF-alpha. In combination with methotrexate, infliximab had been approved for therapy of psoriatic arthritis.

In clinical studies, infliximab had also proven safe and effective in treating plaque-type psoriasis. In 80% of treated patients, PASI (Psoriasis Area and Severity Index) decreased by 75% or greater after 10 weeks of treatment.

The authors reported that infliximab was expected to be approved as second-line therapy in Germany for treatment of psoriasis vulgaris.

Editor’s Note: Methotrexate is a toxic metabolite that acts to counteract folic acid, interfere with cellular reproduction, and is used in treatment of psoriasis, certain cancers, and arthritis.

Main Menu
Health Articles
Health News
Health Research
Site Map

Health Conditions
Cardiovascular Health
Digestive Health
Infectous Diseases
Musculoskeletal Health
Pregnancy & Childbirth
Skin Health

Misc. Health Articles
Presidential Diseases

Medical Research

Psoriasis Overview
Psoriasis Pictures
Research Summaries

©copyright 2004 - Health In Plain English. All Rights Reserved.

Health Articles Health News Health Research Explained in Plain English